Subscribe
Subscribe for the Newsletter
Mobile Navigation
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Experience
Market Research
Directory
Close
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Antibacterial
Sort By
Newest First
Nice Insight is the market research division of That's Nice LLC, the leading marketing agency serving life sciences.
Explore
About Us
Nice Insight
That's Nice
Reach Our Team
Contact Us
Advertise
LinkedIn
My Account
Login
Sign up
Subscribe for the newsletter
© 2026 PHARMA'S ALMANAC. All rights reserved.
Privacy Policy
Terms And Conditions
(28)
1 / 2
Antibiotics R&D
The Rebirth of Antibiotic R&D: New Momentum for an Old Crisis
David Alvaro, Ph.D.
Pharma's Almanac
PAO-12-25-NI-05
Dec 10, 2025
EU Overhaul
Europe’s Pharma Overhaul: How the New Incentive Model Will Reshape Global Innovation Strategy
David Alvaro, Ph.D.
Pharma's Almanac
PAO-11-25-NI-06
Nov 18, 2025
Antibiotics
Kineticos Launches Kinvard Bio to Advance Next-Generation Antibiotics in the Fight Against Antimicrobial Resistance
Kinvard Bio
PR-02-25-NI-27
Feb 24, 2025
Molecular Machines
The Potential of Molecular Machines: Enhanced Drug Delivery and Beyond
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-01-24-NI-02
Jan 22, 2024
Antibiotic Resistance
Antibiotic Resistance: Advances in Understanding and Drug Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-10-022-NI-07
Oct 11, 2022
Antimicrobial
Preserving the Value of Critical Anti-Infectives
Centrient Pharmaceuticals
PAO-04-22-R221-20
Apr 14, 2021
Antibiotics
Sandoz Announces Plans for Joint Investment to Help Strengthen Future of Antibiotics Manufacturing in Europe
Sandoz
PR-M07-20-NI-38
Jul 27, 2020
Nice Insight Overview
Drug Approval Trends: Significant Acceleration in Recent Years
Nigel Walker
Nice Insight
PAP-Q2-20-NI-001
Jul 1, 2020
Molecules
Molecules that Changed Medicine
David Alvaro, Ph.D.; Emilie Branch; Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAP-Q2-20-NI-002
Jul 1, 2020
Novel Antibiotics
Applying a Synthetic Approach to the Development of a New Generation of Antibiotics
James Graham
Recce Pharmaceuticals Ltd.
PAP-Q2-20-CL-019
Jul 1, 2020
FDA Approval
FDA Approves New Antibiotic to Treat Community-Acquired Bacterial Pneumonia
U.S. Food & Drug Administration
PR-M08-19-NI-061
Aug 21, 2019
FDA Approval
U.S. FDA Approved New Antibacterial for Urinary Tract and Abdominal Infections
Pharma's Almanac
PAO-M08-19-NI-015
Aug 7, 2019
Antibiotics
UK Hopes Subscription Payment Model Will Drive Innovation in Antibiotics
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M08-19-NI-006
Aug 1, 2019
Priority Review
Melinta’s Antibiotic Baxdela Gets Priority Review from FDA for CAPB
Pharma's Almanac
PAO-M07-19-NI-005
Jul 1, 2019
Antibiotic Resistant
FIU Scientists Discover New Arsenic-Based Broad-Spectrum Antibiotic
Florida International University
PR-M04-19-NI-058
Apr 18, 2019
Antibiotics
Infectious Diseases Experts Convene to Explore Lifesaving Antibiotic Research Methods
Nice Insight
PR-M11-18-NI-052
Nov 15, 2018
Investment
Qpex Biopharma Announces Closing of $33 Million Series A Financing and Launch of Company to Address Worldwide Problem of Drug-Resistant Infections
Qpex Biopharma
PR-M10-18-NI-087
Oct 25, 2018
Antibiotics
PolyPid Begins Phase 2 Study to Assess Safety and Efficacy of D-PLEX100 in Prevention of Abdominal Surgical Site Infections
PolyPid
PR-M10-18-NI-070
Oct 19, 2018
Antibiotics
The Menarini Group Announces Commercial Agreement for Vabomere, Orbactiv and Minocin in 68 Countries
Menarini Group
PR-M10-18-NI-048
Oct 15, 2018
Drug Development
New Antibiotic to be Tested against Potential Bioweapons
Emilie Branch
Pharma's Almanac
PAO-M07-18-NI-009
Jul 17, 2018
1 / 2